title: A Study of Angiogenesis Markers in Patients with Renal Cell Carcinoma Undergoing Therapy with Sunitinib.
abstract: Sunitinib is a tyrosine kinase inhibitor (TKI) targeting tumour angiogenesis in patients with advanced renal cell carcinoma (RCC). Currently no universally agreed model exists correlating the expression of angiogenesis markers with the success of treatment.
  
  
  
  We retrospectively analysed archival tissue for 59 RCC patients treated with sunitinib. The expression of angiogenesis markers VEGF-A, VEGFR, PDGFββ, PDGFR, CCND1 and CA9 was assessed by immunohistochemistry (IHC) and correlated with overall survival (OS) and progression-free survival (PFS).
  
  
  
  The median OS and median PFS of the whole group of patients was 24.6 months (17.3-34.2) and 19.5 months (11-27) respectively. VEGFA was positive in 29% of tumors, whereas VEGFR was expressed in only 12% of tumours. PDGFββ and its receptor were detected in a minority of cases. CCND1 and CA9 were positive in 44% and 60% of cases.
  
  
  
  The OS and PFS achieved by our patients reflected previous observations seen with sunitinib, but no correlation was found between expression of angiogenesis markers and clinical outcome.
authors.affiliation: University of Birmingham, Birmingham, U.K.
authors.forename: Clive
authors.initials: C
authors.lastname: Stubbs
authors.affiliation: College of Medical and Dental Sciences, University of Birmingham, Birmingham, U.K.
authors.forename: Antonio D
authors.initials: AD
authors.lastname: Bardoli
authors.affiliation: Cancer Research Unit, University of Warwick, Coventry, U.K.
authors.forename: Mehran
authors.initials: M
authors.lastname: Afshar
authors.affiliation: University of Birmingham, Birmingham, U.K.
authors.forename: Sarah
authors.initials: S
authors.lastname: Pirrie
authors.affiliation: University of Birmingham, Birmingham, U.K.
authors.forename: Manuela
authors.initials: M
authors.lastname: Miscoria
authors.affiliation: Birmingham University Hospitals NHS Trust, Birmingham, U.K.
authors.forename: Isabella
authors.initials: I
authors.lastname: Wheeley
authors.affiliation: University of Birmingham, Birmingham, U.K. axb568@student.bham.ac.uk.|Birmingham University Hospitals NHS Trust, Birmingham, U.K.
authors.forename: Emilio
authors.initials: E
authors.lastname: Porfiri
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D000951:Antigens, Neoplasm / Q000378:metabolism; D000077214:Becaplermin; D014408:Biomarkers, Tumor / Q000378:metabolism*; D000071231:Carbonic Anhydrase IX / Q000378:metabolism; D002292:Carcinoma, Renal Cell / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D019938:Cyclin D1 / Q000378:metabolism; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007211:Indoles / Q000494:pharmacology* / Q000627:therapeutic use; D053208:Kaplan-Meier Estimate; D007680:Kidney Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D020574:Proto-Oncogene Proteins c-sis / Q000378:metabolism; D011758:Pyrroles / Q000494:pharmacology* / Q000627:therapeutic use; D017479:Receptors, Platelet-Derived Growth Factor / Q000378:metabolism; D040262:Receptors, Vascular Endothelial Growth Factor / Q000378:metabolism; D000077210:Sunitinib; D016896:Treatment Outcome; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; C530104:CCND1 protein, human; D007211:Indoles; D020574:Proto-Oncogene Proteins c-sis; D011758:Pyrroles; D042461:Vascular Endothelial Growth Factor A; D019938:Cyclin D1; D000077214:Becaplermin; D017479:Receptors, Platelet-Derived Growth Factor; D040262:Receptors, Vascular Endothelial Growth Factor; C089226:CA9 protein, human; D000071231:Carbonic Anhydrase IX; D000077210:Sunitinib
keywords: CA9; CCND1; PDGFR; PDGFββ; Renal cell carcinoma; VEGF-A; VEGFR; angiogenesis; outcome; sunitinib; survival